2023
DOI: 10.1016/j.ymgme.2022.107285
|View full text |Cite
|
Sign up to set email alerts
|

An engineered β-galactosidase with improved stability and cross-correction for the potential treatment of GM1 Gangliosidosis via AAV gene therapy

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles